Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Active Filter(s):
Details:
Under the initial term of the agreement, Nabriva was solely responsible for marketing, sales, and distribution of SIVEXTRO (Tedizolid Phosphate) in the United States through December 31, 2023. The amendment extends the agreement to December 31, 2026.
Lead Product(s): Tedizolid
Therapeutic Area: Infections and Infectious Diseases Product Name: Sivextro
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 05, 2022
Details:
Under the terms of the agreement, Nabriva will procure SIVEXTRO from Merck & Co. Inc., Kenilworth, N.J., USA and be responsible for marketing, sales, and distribution of SIVEXTRO in the U.S. through December 31, 2023, with renewable three-year extensions.
Lead Product(s): Tedizolid
Therapeutic Area: Infections and Infectious Diseases Product Name: Sivextro
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 15, 2020
